NCT03014479 - Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

219

Participants

Timeline

Start Date

February 18, 2017

Primary Completion Date

October 21, 2017

Study Completion Date

October 21, 2017

Conditions

Type 2 Diabetes

Interventions

DRUG

Trelagliptin

Trelagliptin 100 mg or 50 mg

DRUG

Daily DPP-4 inhibitor

Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin

Trial Locations (27)

Takeda Selected Site 17, Nagoya

Takeda Selected Site 18, Nagoya

Takeda Selected Site 25, Obata

Takeda Selected Site 9, Kobe

Takeda Selected Site 27, Koga

Takeda Selected Site 14, Kawasaki

Takeda Selected Site 11, Sagamihara

Takeda Selected Site 10, Yamato

Takeda Selected Site 4, Sendai

Takeda Selected Site 5, Sendai

Takeda Selected Site 3, Kashihara

Takeda Selected Site 15, Kashihara

Takeda Selected Site 1, Suita

Takeda Selected Site 24, Okegawa

Takeda Selected Site 26, Oyama

Takeda Selected Site 23, Adachi-ku

Takeda Selected Site 6, Chuo-ku

Takeda Selected Site 7, Chuo-ku

Takeda Selected Site 22, Edogawa-ku

Takeda Selected Site 19, Musashino

Takeda Selected Site 21, Ōta-ku

Takeda Selected Site 12, Shibuya-ku

Takeda Selected Site 13, Shinagawa-ku

Takeda Selected Site 20, Shinagawa-ku

Takeda Selected Site 2, Shinjuku-ku

Takeda Selected Site 8, Shinjuku-ku

Takeda Selected Site 16, Osaka